Haridas B. Rode

Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation

Martin L. Sos, Haridas B. Rode, Stefanie Heynck et al. · Cancer Research · 2010 · 218 citations · Full text

Irreversible Egfr Inhibitors, Engineering, Tumor Cells +20

Structure-guided development of affinity probes for tyrosine kinases using chemical genetics

Jimmy A. Blair, Daniel Rauh, Charles Kung et al. · Nature Chemical Biology · 2007 · 201 citations · Full text

Chemical Biology, Chemical Genetics, Drug Target +12

Hybrid Compound Design To Overcome the Gatekeeper T338M Mutation in cSrc

Matthäus Getlik, Christian Grütter, Jeffrey R. Simard et al. · Journal of Medicinal Chemistry · 2009 · 141 citations · Full text

Drug Target, Engineering, Hybrid Compound Design +16

A new screening assay for allosteric inhibitors of cSrc

Jeffrey R. Simard, Sabine Klüter, Christian Grütter et al. · Nature Chemical Biology · 2009 · 125 citations · Full text

Medicinal Chemistry, New Screening Assay, Medicine +4

Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR

Sabine Klüter, Haridas B. Rode, Jeffrey R. Simard et al. · Bioorganic & Medicinal Chemistry · 2008 · 89 citations · Full text

Drug Target, Medicine, Rational Drug Design +9